Hemostatic effects of simvastatin in subjects with impaired fasting glucose

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 1090-1098

  Krysiak, Robert ^a   Gdula Dymek, Anna ^a   Okopieñ, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Factor VII; Fibrinogen; Hypercholesterolemia; Impaired fasting glucose; Plasminogen activator inhibitor 1 (PAI 1); Simvastatin

Indexed keywords

BLOOD CLOTTING FACTOR 7; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; PLASMINOGEN ACTIVATOR INHIBITOR 1; SIMVASTATIN;

ADULT; ARTICLE; BEDTIME DOSAGE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RISK ASSESSMENT;

EID: 79551478959     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70371-6     Document Type: Article

References (30)

1. Atalar E, Ozmen F, Haznedaroglu I, Acil T, Ozer N, Ovunc K, Aksoyek S, Kes S: Effect of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease. Int J Cardiol, 2002, 84, 227-231.
2. Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP: Pleiotropic effects of statins-clinical evidence. Curr Pharm Des, 2009, 15, 479-489.
3. Bulcão C, Giuffrida FM, Ribeiro-Filho FF, Ferreira SR: Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity? Braz J Med Biol Res, 2007, 40, 229-235.
4. Bulcão C, Ribeiro-Filho FF, Sañudo A, Roberta Ferreira SG: Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs, 2007, 7, 219-224.
5. Chruoeciel P, Goch A, Banach M, Mikhailidis DP, Rysz J, Goch JH: Circadian changes in the hemostatic system in healthy men and patients with cardiovascular diseases. Med Sci Monit, 2009, 15, RA203-RA208.
6. Di Garbo V, Bono M, Di Raimondo D, De Simone R, Raneli G, Avellone G: Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. Thromb Haemost, 2000, 83, 688-692.
7. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation, 2001, 103, 357-362.
8. Goldberg RB: Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab, 2009, 9, 3171-3182.
9. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 7-22. (Pubitemid 34756487)
10. Jasiñska M, Owczarek J, Orszulak-Michalak D: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep, 2007, 59, 483-499.
11. Kannel WB: Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids, 2005, 40, 1215-1220.
12. Kher N, Marsh JD: Pathobiology of atherosclerosis - a brief review. Semin Thromb Hemost, 2004, 30, 665-672.
13. Kita T, Kume N, Minami M, Hayashida K, Murayama T, Sano H, Moriwaki H et al.: Role of oxidized LDL in atherosclerosis. Ann NY Acad Sci, 2001, 947, 199-205.
14. Krysiak R, Łabuzek K, Okopieñ B: Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep, 2009, 61, 1134-1145.
15. Krysiak R, Okopieñ B, Herman ZS: Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs, 2003, 63, 1821-1854. (Pubitemid 37083030)
16. Krysiak R, Stachura-Kułach A, Okopieñ B: Metabolic and monocyte-suppressing action of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism abnormalities. Pharmacol Rep, 2010, 62, 120-130.
17. Ludwig S, Dharmalingam S, Erickson-Nesmith S, Ren S, Zhu F, Ma GM, Zhao R et al.: Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus. Diabetes Res Clin Pract, 2005, 70, 110-118.
18. Okopieñ B, Krysiak R, Herman ZS: Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab, 2006, 91, 1770-1778.
19. Okopieñ B, Krysiak R, Madej A, Belowski D, Zieliñski M, Kowalski J, Herman ZS: Effect of simvastatin and fluvastatin on plasma fibrinogen levels in patients with primary hypercholesterolemia. Pol J Pharmacol, 2004, 56, 781-787.
20. Petersen JL, McGuire DK: Impaired glucose tolerance and impaired fasting glucose - a review of diagnosis, clinical implications and management. Diab Vasc Dis Res, 2005, 2, 9-15.
21. Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y, Zhang M: Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res, 2009, 26, 958-964.
22. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJ, Koenig Wet al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008, 359, 2195-2207.
23. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Canon CP: High dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation, 2004, 110, Suppl, S834.
24. Saigo M, Hsue PY, Waters DD: Role of thrombotic and fibrinolytic factors in acute coronary syndromes. Prog Cardiovasc Dis, 2004, 465, 524-538. (Pubitemid 38781093)
25. Sarwar N, Thompson AJ, Di Angelantonio E: Markers of inflammation and risk of coronary heart disease. Dis Markers, 2009, 26, 217-225.
26. Song JC, White CM: Do HMG-CoA reductase inhibitors affect fibrinogen? Ann Pharmacother, 2001, 35, 236-241.
27. Tsikouris JP, Suarez JA, Meyerrose GE: Plasminogen activator inhibitor-1: physiological role, regulation, and the influence of common pharmacologic agents. J Clin Pharmacol, 2002, 42, 1187-1192.
28. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR; Australian Diabetes Society; Australian Diabetes Educators Association: Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust, 2007, 186, 461-465.
29. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A: Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation, 2001, 103, 2248-2253. (Pubitemid 32433713)
30. Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y: Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb, 2008, 15, 269-275.